NXTC Stock Overview
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
NextCure, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.66 |
| 52 Week High | US$5.54 |
| 52 Week Low | US$1.16 |
| Beta | -0.023 |
| 1 Month Change | 2.47% |
| 3 Month Change | -2.92% |
| 1 Year Change | -68.91% |
| 3 Year Change | -96.33% |
| 5 Year Change | n/a |
| Change since IPO | -91.66% |
Recent News & Updates
Recent updates
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate
Nov 22
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)
Aug 09NextCure GAAP EPS of -$0.59
Aug 04We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate
May 02NextCure: Large Upside With Downside Protected By Cash Pile
Sep 29NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow
May 10NextCure EPS misses by $0.01
May 06Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like
Feb 12NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares
Jan 08NextCure provides update on NC318 clinical program
Dec 17Shareholder Returns
| NXTC | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -0.6% | -0.8% | 1.7% |
| 1Y | -68.9% | 4.3% | -9.6% |
Return vs Industry: NXTC underperformed the US Biotechs industry which returned 4.4% over the past year.
Return vs Market: NXTC underperformed the US Market which returned -9.6% over the past year.
Price Volatility
| NXTC volatility | |
|---|---|
| NXTC Average Weekly Movement | 10.0% |
| Biotechs Industry Average Movement | 12.1% |
| Market Average Movement | 6.7% |
| 10% most volatile stocks in US Market | 17.5% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NXTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: NXTC's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 87 | Michael Richman | https://www.nextcure.com |
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells.
NextCure, Inc. Fundamentals Summary
| NXTC fundamental statistics | |
|---|---|
| Market Cap | US$46.11m |
| Earnings (TTM) | -US$74.37m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.6x
P/E RatioIs NXTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NXTC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$4.08m |
| Gross Profit | -US$4.08m |
| Other Expenses | US$70.29m |
| Earnings | -US$74.37m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.68 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did NXTC perform over the long term?
See historical performance and comparison